N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients

Journal of Infection

Volumn 35, Issue 2, 1997, Pages 143-147

  Akerlund B ^a   Tynell, E ^b   Bratt, G ^c   Bielenstein, M ^d   Lidman, C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d Apoteksbolaget AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; CYSTEINE; GLUTATHIONE; NUCLEOSIDE ANALOG;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG TOXICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; RANDOMIZED CONTROLLED TRIAL; RISK;

EID: 0030680237     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)91578-4     Document Type: Article

References (20)

1. Coopman S, Johnson R, Platt R, Stern R. Cutaneous drug reactions in HIV infection. N Engl J Med 1993; 328: 1670-1674.
2. Jacobsson M, Busch C, Child C. Toxicity of clindamycin as prophylaxis for AIDS associated toxoplasma encephalitis. Lancet 1992; 339: 333-334.
3. Small P, Schnecter G, Goodman P. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
4. Lidman C, Örtquist Å, Lundberg P, Julander I, Bergdahl S. Pneumocystis carinii pneumonia in Stockholm: one year follow-up and pyrimethamine prophylaxis. Scand J Infect Dis 1989; 21: 381-387.
5. Kovacs J, Hiemens J, Mancher A. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiences. Ann Int Med 1984; 100: 663-671.
6. Rushin J, La Riviera M. Low dose cotrimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency disease. Lancet 1991; 337: 468-471.
7. Reider M, Shear H, Kanee A, Tang B, Spielberg S. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-17.
8. Price-Evans D, Kalow W, ed. Pharmacogenetics of drug metabolism of sulphamethoxazole. New York: Perganon Press Inc., 1992.
9. Rieder J, Krause R, Bird I, Dekaban G. Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected and non-infected cells. J Acquir Immune Defic Syndr 1995; 8: 134-140.
10. van der Ven A, Vree T, Coopmans K, van der Meer J. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV seropositive patients compared to healthy volunteers. Br J Clin Pharmacol 1994; 38: 147-150.
11. Carr A, Swanson C, Penny R, Cooper D. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulphamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167: 180-185.
12. Jarstrand C, Åkerlund B, Lindeke B. Increased nitroblue tetrazolium (NBT) reduction and low cysteine levels in asymptomatic HIV positive patients. Lancet 1990; 335: 235.
13. Staal F, Ela S, Roederer M, Anderson M, Herzenberg L. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992; 339: 909-912.
14. Sheffner A, Medler E, Bailey K, Gallo D, Mueller A, Sarret H. Metabolic studies with N-acetylcysteine in plasma by ion-pair derivatization. J Chromatogr 1966; 432: 65-74.
15. Halliwell B. Oxidants and human disease: some new concepts. FASEB 1987; 1: 358-364.
16. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking induced lung disease. XX Radiol Biol Med 1996; 21: 669-681.
17. Placidi L, Cretton E, Placidi M, Sopmadossi J. Reduction of 3′-ado-3′-deoxythymidine to 3′-amino-3′deoxythymidine in human liver microsomes and its relationship to cytochrome P450. Clin Pharmacol Ther 1993; 54: 168-176.
18. Sönnerborg A, Jarstrand C. Nitroblue tetrazolium (NBT) reduction by neutrophilic granulocytes in patients with HTLV-III infection. Scan J Infect Dis 1986; 18: 101-103.
19. de Quay B, Malinverni R, Lautenberg B. Glutathione depletion in HIV infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 1992; 6: 815-819.
20. Åkerlund B, Jarstrand C, Lindeke B, Sönnetborg A, Åkerblad A-C, Rasool O. The effect of N-acetylcysteine (NAC) treatment in HIV-1 infection - a double blind placebo controlled trial. Eur Clin Pharmacol 1996; 50: 457-461.